Tetraphase Pharmaceuticals to Host Fourth Quarter and Full-Year 2018 Financial Results Conference Call
March 07 2019 - 4:03PM
Business Wire
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a
biopharmaceutical company focused on developing and commercializing
novel tetracyclines to treat serious and life-threatening
conditions, today announced that company management will host a
conference call at 4:30 p.m. ET on Thursday, March 14, 2019 to
discuss fourth quarter and full-year 2018 financial results and
provide a general corporate update.
The conference call may be accessed by dialing 844-831-4023
(U.S. and Canada) or 731-256-5215 (international) and entering
conference ID number 4187876. A live audio webcast of the
conference call will be available online from the “Investors –
Events & Presentations” section of the Tetraphase website at
www.tphase.com.
A replay of the conference call will be available from 7:30 p.m.
ET on Thursday, March 14, 2019, through 7:30 p.m. ET on Thursday,
March 21, 2019 by dialing 855-859-2056 (U.S. and Canada) and
404-537-3406 for (international) callers. The conference ID number
is 4187876. A replay of the webcast will be available by visiting
Tetraphase’s website.
About Tetraphase Pharmaceuticals, Inc.
Tetraphase Pharmaceuticals, Inc., is a biopharmaceutical company
using its proprietary chemistry technology to create novel
tetracyclines for serious and life-threatening conditions,
including bacterial infections caused by many of the
multidrug-resistant bacteria highlighted as urgent public health
threats by the World Health Organization and the Centers for
Disease Control and Prevention. The Company has created more than
3,000 novel tetracycline compounds using its proprietary technology
platform. Tetraphase's lead product XERAVATM is approved for the
treatment of complicated intra-abdominal infections by the U.S.
Food and Drug Administration and the European Medicines Agency. The
Company’s pipeline also includes TP-271 and TP-6076, which are in
Phase 1 clinical trials and TP-2846 which is in preclinical testing
for acute myeloid leukemia. Please visit www.tphase.com for more
company information.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190307005068/en/
Jennifer Vierajviera@tphase.com617-600-7040
Tetraphase Pharmaceuticals (NASDAQ:TTPH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Tetraphase Pharmaceuticals (NASDAQ:TTPH)
Historical Stock Chart
From Apr 2023 to Apr 2024